Your browser doesn't support javascript.
loading
Soluble urokinase plasminogen activator receptor (suPAR) in the emergency department: An update.
Velissaris, Dimitrios; Zareifopoulos, Nicholas; Karamouzos, Vasileios; Pierrakos, Charalampos; Karanikolas, Menelaos.
Afiliación
  • Velissaris D; Department of Internal Medicine, University Hospital of Patras, Patras, Greece.
  • Zareifopoulos N; Department of Internal Medicine, University Hospital of Patras, Patras, Greece.
  • Karamouzos V; Intensive Care Unit, University Hospital of Patras, Patras, Greece.
  • Pierrakos C; Department of Intensive Care, Brugmann University Hospital, Université Libre de Bruxelles, Brussels, Belgium.
  • Karanikolas M; Department of Anesthesiology, Washington University School of Medicine, St. Louis, MO, USA.
Caspian J Intern Med ; 13(4): 650-665, 2022.
Article en En | MEDLINE | ID: mdl-36420338
ABSTRACT

Background:

The biomarker soluble urokinase plasminogen activator receptor (suPAR) is an indicator of inflammation which is increased in a variety of chronic and acute disease states. Its most promising application in the emergency setting is to aid in the prognostic stratification of patients by identifying those at high risk of deterioration. This is a narrative review of studies evaluating the use of suPAR.

Methods:

We conducted a Medline search for studies on the use of suPAR in patients acutely admitted to the emergency department.

Results:

25 original studies were included in the review. suPAR as a marker of inflammation has been used alone or combined to other inflammatory biomarkers in the assessment of patients suffering from various acute and chronic diseases in an emergency setting. As it is non-specific, it may increase in infectious disease, malignancy or acute coronary syndromes among other conditions, but quantitative suPAR levels correlate with disease severity. It may be useful for the identification of high risk patients regardless of underlying pathology.

Conclusion:

As the ideal biomarker in the emergency setting has not been identified yet, suPAR may be a promising addition to the established biomarkers for the initial assessment of patients in this setting. Additional research is necessary to evaluate the usefulness of suPAR guided management algorithms.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Caspian J Intern Med Año: 2022 Tipo del documento: Article País de afiliación: Grecia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Caspian J Intern Med Año: 2022 Tipo del documento: Article País de afiliación: Grecia